Jonathan Young - 27 Dec 2023 Form 4 Insider Report for Akero Therapeutics, Inc. (AKRO)

Role
Chief Operating Officer
Signature
/s/ Jonathan Young
Issuer symbol
AKRO
Transactions as of
27 Dec 2023
Net transactions value
-$95,503
Form type
4
Filing time
29 Dec 2023, 20:30:36 UTC
Previous filing
18 Dec 2023
Next filing
05 Mar 2024
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AKRO Common Stock Options Exercise $34,433 +5,414 +2.9% $6.36* 190,545 27 Dec 2023 Direct
transaction AKRO Common Stock Sale $129,936 -5,414 -2.8% $24.00 185,131 27 Dec 2023 Direct F3
holding AKRO Common Stock 20,000 27 Dec 2023 By EA Irrevocable Trust F1
holding AKRO Common Stock 20,000 27 Dec 2023 By CM Irrevocable Trust F1
holding AKRO Common Stock 20,000 27 Dec 2023 By JL Irrevocable Trust F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AKRO Stock Option (Right to Buy) Options Exercise $0 -5,414 -11% $0.000000 43,064 27 Dec 2023 Common Stock 5,414 $6.36 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares are held in irrevocable trusts for the benefit of the Reporting Person's children. The Reporting Person's spouse is trustee of the trusts. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.
F2 The options are vested and currently exercisable.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $24.0000 to $24.0003, inclusive.